 TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announced a collaboration with resTORbio, Inc. Nasdaq: TORC. resTORbio is a clinical-stage biotechnology company developing innovative medicines that target the biology of aging to treat aging-related diseases. 